Pages that link to "Q15753218"
Jump to navigation
Jump to search
The following pages link to Clinical Neuropharmacology (Q15753218):
Displaying 50 items.
- (Q19843471) (redirect page) (← links)
- Methylphenidate-Induced Psychosis in Adult Attention-Deficit/Hyperactivity Disorder (Q22242689) (← links)
- Abuse liability of bretazenil and other partial agonists (Q28182785) (← links)
- Clinical evidence of an interaction between imipramine and acetylsalicylic acid on protein binding in depressed patients (Q28192392) (← links)
- Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients (Q28196582) (← links)
- The significance of prestroke aspirin dosage in fatal outcome of acute stroke (Q28211510) (← links)
- Piribedil-induced sleep attacks in patients without Parkinson disease: a case series (Q28237962) (← links)
- Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder pa (Q28238749) (← links)
- Safety and efficacy during long-term treatment with moclobemide (Q28240202) (← links)
- Moclobemide in social phobia: a pilot open study. GRP Group. Groupe de Recherche en Psychopharmacologie (Q28240212) (← links)
- Tolcapone: an efficacy and safety review (2007) (Q28251612) (← links)
- A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study (Q28254588) (← links)
- Neurobiological mechanisms involved in antidepressant therapies (Q28255523) (← links)
- Modulatory role for CCK-B antagonists in Parkinson's disease (Q28259025) (← links)
- The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine (Q28259655) (← links)
- Efficacy of moclobemide in different patient groups. Results of new subscales of the Hamilton Depression Rating Scale (Q28259665) (← links)
- Reversible monoamine oxidase-A inhibitors in resistant major depression (Q28259676) (← links)
- Pharmacology of moclobemide (Q28259688) (← links)
- Homer's moly identified as Galanthus nivalis L.: physiologic antidote to stramonium poisoning (Q28266351) (← links)
- Impulse control disorder and piribedil: report of 5 cases (Q28266523) (← links)
- Quazepam, a sedative-hypnotic selective for the benzodiazepine type 1 receptor: autoradiographic localization in rat and human brain (Q28282546) (← links)
- Antidepressant and anxiolytic activities of tianeptine: an overview of clinical trials (Q28283827) (← links)
- Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease (Q28290843) (← links)
- Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and in populations with risk factors (Q28292210) (← links)
- Impulse control disorders arising in 3 patients treated with rotigotine (Q28299492) (← links)
- Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia (Q28300471) (← links)
- Dihydroergocryptine in the treatment of Parkinson's disease: a six months' double-blind clinical trial (Q28301727) (← links)
- Treatment of psychogenic polydipsia with acetazolamide: a report of 5 cases (Q28303505) (← links)
- Cladribine: mode of action and implications for treatment of multiple sclerosis (Q28303514) (← links)
- Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis (Q28307168) (← links)
- Cinnarizine-induced parkinsonism in primates (Q28316206) (← links)
- Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patients (Q28317148) (← links)
- Amnestic syndrome associated with propranolol toxicity: a case report (Q28317150) (← links)
- Antagonist effect of terguride in Parkinson's disease (Q28323088) (← links)
- Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo (Q28323104) (← links)
- Clenbuterol-Induced Tardive Dyskinesia (Q28324716) (← links)
- Acute Dystonia Induced by Sulpiride (Q28324718) (← links)
- Serotonin Reuptake Inhibitors, Paranoia, and the Ventral Basal Ganglia (Q28326708) (← links)
- A blinded study of the suppressibility of involuntary movements in Huntington's chorea, tardive dyskinesia, and L-dopa-induced chorea (Q28329990) (← links)
- Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys (Q28332555) (← links)
- Complex dystonia of Parkinson's disease: clinical features and relation to plasma levodopa profile (Q28334703) (← links)
- Evidence for the role of spinal cord systems in Parkinson's disease-associated pain (Q28334706) (← links)
- Tardive dyskinesia induced by sulpiride (Q28335414) (← links)
- Migraine attacks induced by subcutaneous apomorphine in two migrainous parkinsonian patients (Q28335416) (← links)
- Metoclopramide-induced parkinsonism (Q28339157) (← links)
- Lithium-induced internuclear ophthalmoplegia (Q28340894) (← links)
- Carbamazepine-induced tics (Q28342073) (← links)
- Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease (Q28370400) (← links)
- Sumatriptan and ergotamine overuse and drug-induced headache: a clinicoepidemiologic study (Q28370593) (← links)
- Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations (Q28370599) (← links)